Nicox NCX 470 NDA accepted for review by China's NMPA
Nicox SA has confirmed that China's National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for NCX 470, its nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The dossier was submitted in August 2026 by Ocumension Therapeutics, Nicox's exclusive licensee for the Chinese, Korean and Southeast Asian markets, and the formal acceptance was confirmed on 10 September 2026.
NCX 470, known as OT-301 in Ocumension's portfolio, is designed to release both bimatoprost and nitric oxide into the eye, targeting two independent IOP-lowering pathways. The prostaglandin analogue component reduces IOP via established outflow mechanisms, while the nitric oxide element activates soluble guanylate cyclase to enhance aqueous humour drainage through the trabecular meshwork. The company positions the dual-mechanism approach as differentiating NCX 470 from single-pathway competitors, though clinical superiority over existing prostaglandin analogues will ultimately be judged by regulators and clinicians on the basis of head-to-head data.
Regulatory calendar
The NMPA review process for pharmaceutical products has no fixed statutory timeline, though industry experience suggests decisions typically follow within 12 to 18 months of submission. A Chinese regulatory decision is therefore expected in late 2027 or early 2028, likely following the US PDUFA date of 30 April 2027, by which the FDA is due to complete its own NDA review. Nicox said a US launch is targeted for the second half of 2027, subject to FDA approval. Phase 3 trials in Japan are ongoing, and results remain a further milestone to watch.
Gavin Spencer, chief executive of Nicox, said the acceptance "initiates the examination process and is another key step towards commercialisation" of NCX 470 in China. Ocumension already maintains an ophthalmology sales force across China, which Nicox has pointed to as a factor that could accelerate a commercial launch following approval.
Commercial terms and market context
Ocumension has paid Nicox licence fees totalling €18 million for rights covering China, Korea and Southeast Asia, contributed 50% of the costs of the Denali Phase 3 trial, and holds a stake in Nicox as a principal shareholder. On commercialisation, Nicox is entitled to tiered royalties on Ocumension's net sales of NCX 470, ranging from 6% to 12%.
The glaucoma market in China is substantial and growing, driven by an ageing population and rising rates of diagnosis as screening infrastructure improves. Prostaglandin analogues are the established first-line standard of care globally, and generic versions are widely available. For a novel entrant such as NCX 470 to gain meaningful share, Ocumension will need to demonstrate a clinically meaningful benefit over generic bimatoprost or latanoprost, both on efficacy and tolerability grounds, in a market that remains highly price-sensitive. Whether the nitric oxide-donating mechanism translates into a sufficiently distinct clinical profile to support premium pricing will be a key commercial question.
At the global level, Nicox has also licensed NCX 470 to Kowa for markets outside China, Korea, Southeast Asia and the United States, adding a further potential royalty stream as the asset progresses through regulatory review in multiple jurisdictions simultaneously. The parallel-track regulatory strategy, spanning the US, China and Japan, is a relatively ambitious posture for a Euronext Growth-listed company of Nicox's size, and execution risk across all three timelines will be a point of scrutiny for investors monitoring the PDUFA date next April.